Is Primary Myelofibrosis Hereditary?

Primary myelofibrosis is not a hereditary disease and cannot be directly passed from parents to their children. Its onset is predominantly associated with acquired gene mutations in hematopoietic stem cells, and familial clustering of cases is extremely rare. Persistent fatigue and splenomegaly warrant prompt medical evaluation for diagnosis.

Primary myelofibrosis is a hematologic disorder caused by abnormal bone marrow hematopoiesis, with the core pathogenic mechanism being somatic gene mutations in hematopoietic stem cells. External environmental triggers or metabolic abnormalities may precipitate disease onset—distinctly different from the transmission patterns observed in conventional inherited disorders. First-degree relatives need not be overly concerned about genetic risk and do not require specific screening; maintaining routine daily life and health practices is sufficient.

In clinical practice, treatment for primary myelofibrosis is individualized. For mild cases, regular monitoring of complete blood counts and bone marrow parameters is the mainstay, aiming to maintain stable systemic condition. Patients with progressive disease may receive pharmacologic therapy to modulate hematopoiesis and alleviate symptoms such as splenomegaly and anemia. In severe or advanced cases, allogeneic hematopoietic stem cell transplantation may be considered to restore normal hematopoietic and immune function.

Adopting regular sleep-wake cycles and a balanced diet—including high-quality protein and diverse essential nutrients—helps sustain immune competence. Avoiding excessive physical exertion, infections, and other potential triggers contributes to stabilizing physiological function and slowing disease progression.